In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting

Chen, Jianqing; Giblin, Michael F.; Wang, Nannan; Jurisson, Silvia S.; Quinn, Thomas P.

doi:10.1016/s0969-8051(99)00032-3

Cited by 55 publications

(73 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Low K D and high tumor uptake values for the radioiodinated peptides were observed. The biodistribution of NDP in B16/F1 murine melanomabearing C57 BL/6 mice labeled with 125 I using chloramine T was reported in our previous work (26). From the biodistribution data, the conjugation labeling approach showed several advantages over direct labeling, including significantly lower stomach and thyroid uptake than was observed using the chloramine-T method at all time points investigated, indicating a decrease in the in vivo deiodination of the radiolabeled complex.…”

Section: Discussionmentioning

confidence: 59%

“…Efforts to develop radiohalogenated ␣-MSH analogs for melanoma targeting have been disappointing for the most part. Radiolabeling of the gold standard ␣-MSH analog, [Nle 4 ,D-Phe 7 ]␣-MSH (NDP), directly with 125 I at the Tyr 2 residue resulted in very slow clearance (low tumor:blood ratios) and in vivo deiodination, making it unsuitable for melanoma radioimaging or radiotherapy (26). NDP labeled with N-succinimidyl-3-iodobenzoate ( 125 I-SIB) at Lys 11 residues to give 125 I-3-or 4-iodobenzoate (IBA)-NDP (conjugate labeling approach) resulted in increased affinity (lower K D ; 10 versus 140 pM) and significantly lower thyroid and stomach uptake than 125 I-Tyr 2 -NDP in normal mice (7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radioiodination of Rhenium Cyclized α-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma

Cheng¹,

Chen

Quinn

et al. 2004

Cancer Research

Self Cite

View full text Add to dashboard Cite

Radiohalogenated ␣-melanocyte-stimulating hormone (␣-MSH) analogs were proposed for melanoma imaging and potential radiotherapy because ␣-MSH receptors are overexpressed on both mouse and human melanoma cell lines. However, biodistribution studies in tumor-bearing mice with radiohalogenated ␣-MSH peptides showed very rapid tumor radioactivity wash out due to lysosomal degradation of the radiohalogenated complex after internalization, which decreased the therapeutic efficacy significantly (

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Introductionmentioning

confidence: 99%

Radioiodination of Rhenium Cyclized α-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma

Cheng¹,

Chen

Quinn

et al. 2004

Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several α-MSH analogs which can recognize the MC1R have been labeled with different radionuclides for melanoma detection and radiotherapy (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(26)(27)(28). The most promising melanoma-targeting peptides are linear peptide NAPamide (16) and rhenium-cyclized CCMSH peptides (9,11,15).…”

Section: Discussionmentioning

confidence: 99%

⁶⁴Cu-Labeled Alpha-Melanocyte-Stimulating Hormone Analog for MicroPET Imaging of Melanocortin 1 Receptor Expression

et al. 2007

View full text Add to dashboard Cite

The alpha-melanocyte-stimulating hormone (α-MSH) receptor (melanocortin type 1 receptor, or MC1R) plays an important role in the development and growth of melanoma cells. It was found that MC1R was overexpressed on most murine and human melanoma, making it a promising molecular target for melanoma imaging and therapy. Radiolabeled α-MSH peptide and its analogs that can specifically bind with MC1R have been extensively explored for developing novel agents for melanoma detection and radionuclide therapy. The goal of this study was to evaluate a 64 Culabeled α-MSH analog, Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys(DOTA)-NH 2 (DOTANAPamide), as a potential molecular probe for microPET imaging of melanoma and MC1R expression in melanoma xenografted mouse models. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) conjugated NAPamide was synthesized and radiolabeled with 64 Cu (t 1/2 =12 h) in NH 4 OAc (0.1 M; pH 5.5) buffered solution for 60 min at 50 °C. Cell culture studies reveal rapid and high uptake and internalization of 64 Cu-DOTA-NAPamide in B16F10 cells. Over 90% of receptor-bound tracer is internalized at 3 h incubation. A cellular retention study demonstrates that the receptor-bound 64 Cu-DOTA-NAPamide is slowly released from the B16F10 cells into the medium; 66% of the radioactivity is still associated with the cells even after 3 h incubation. The biodistribution of 64 Cu-DOTA-NAPamide was then investigated in C57BL/6 mice bearing subcutaneous murine B16F10 melanoma tumors with high capacity of MC1R and Fox Chase Scid mice bearing human A375M melanoma with a relatively low number of MC1R receptors. Tumor uptake values of 64 Cu-DOTA-NAPamide are found to be 4.63 ± 0.45% and 2.49 ± 0.31% ID/g in B16F10 and A375M xenografted melanoma at 2 h postinjection (pi), respectively. The B16F10 tumor uptake at 2 h pi is further inhibited to 2.29 ± 0.24% ID/g, while A375M tumor uptake at 2 h pi remains 2.20 ± 0.41% ID/g with a coinjection of excess α-MSH peptide. MicroPET imaging of 64 Cu-DOTA-NAPamide in B16F10 tumor mice clearly shows good tumor localization. However, low A375M tumor uptake and poor tumor to normal tissue

show abstract

“…22,23 For [ 18 F]FIB-PRGD2 we noted a slightly higher tumoral uptake in α v β 3 integrin positive tumors than in those determined with PRGD2 labeled with other 18 F-prosthetic groups. 24,25 No defluorination was observed for either radiopeptide between 1 and 3 h p.i.…”

Section: I]/[mentioning

confidence: 76%

Development and Preliminary Evaluation of TFIB, a New Bimodal Prosthetic Group for Bioactive Molecule Labeling

Billaud

Vidal

Vincenot

et al. 2014

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

ABSTRACT:The new readily available prosthetic group, tetrafluorophenyl 4-fluoro-3-iodobenzoate (TFIB), designed for both molecular imaging and targeted radionuclide therapy purposes was radiolabeled either with fluorine or iodine radionuclides with excellent radiochemical yields and purities. These radiolabeled tags were conjugated to N,N-diethylethylenediamine to give melanin-targeting radiotracers [

show abstract

In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting

Cited by 55 publications

References 27 publications

Radioiodination of Rhenium Cyclized α-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma

Radioiodination of Rhenium Cyclized α-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma

⁶⁴Cu-Labeled Alpha-Melanocyte-Stimulating Hormone Analog for MicroPET Imaging of Melanocortin 1 Receptor Expression

Development and Preliminary Evaluation of TFIB, a New Bimodal Prosthetic Group for Bioactive Molecule Labeling

Contact Info

Product

Resources

About

In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting

Cited by 55 publications

References 27 publications

Radioiodination of Rhenium Cyclized α-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma

Radioiodination of Rhenium Cyclized α-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma

64Cu-Labeled Alpha-Melanocyte-Stimulating Hormone Analog for MicroPET Imaging of Melanocortin 1 Receptor Expression

Development and Preliminary Evaluation of TFIB, a New Bimodal Prosthetic Group for Bioactive Molecule Labeling

Contact Info

Product

Resources

About

⁶⁴Cu-Labeled Alpha-Melanocyte-Stimulating Hormone Analog for MicroPET Imaging of Melanocortin 1 Receptor Expression